May 2011, Vol 4, No 3

Impaired Hydroxylation of 5-Methylcytosine in TET2-Mutated Myeloid Malignancies
Read More ›

Serum Albumin Affects Methotrexate Level Variability and Methotrexate Toxicity
Read More ›

ACOSOG Z1031: Neoadjuvant Comparison between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor–Rich Stage 2/3 Breast Cancer
Read More ›

Follicular lymphoma (FL) is one of the most common subtypes of indolent non-Hodgkin lymphoma (NHL). Although FL is considered incurable with currently available therapy, the introduction of monoclonal antibodies has improved clinical outcomes for this group of patients. Ongoing research focuses on assisting practicing oncologists with selecting the proper therapeutic options for specific clinical scenarios. Read More ›

Pancreatic neuroendocrine tumor (PNET) refers to several tumor types located in the pancreas. These tumors are classified as functional or nonfunctional depending on production and secretion of bioactive hormones. Functional PNETs cause clinical symptoms associated with their tumor classification. Read More ›

Clear cell (CC)-renal cell carcinoma (RCC), the predominant histologic type of RCC, is highly dependent on angiogenesis, via the vascular endothelial growth factor (VEGF) pathway.¹ The mammalian target of rapamycin (mTOR) pathway also appears to play a role in VEGF production, as well as directly promote tumor cell growth.

Read More ›

Read More ›

Breast cancer is the most common cancer among women. In 2010, there were an estimated 207,090 new cases and 39,840 deaths.¹ Despite many improvements in the treatment of breast cancer, about 20% to 30% of women with the disease will progress to metastatic breast cancer (MBC). Although MBC remains incurable, a variety of treatment options are available. The US Food and Drug Administration (FDA) recently approved eribulin (Halaven), providing an exciting new option for women with heavily pretreated MBC.

Read More ›